“The discovery of oncology therapies is continuing at an unprecedented pace,” said Michele Becci, vice president of industry strategy at Medidata. “Medidata's unified platform empowers clinical teams to drive more effective and efficient research, and speed delivery of targeted cancer therapies to patients who need them.”

The Medidata Clinical Cloud® provides comprehensive analytics and technology to tackle today’s challenges impacting precision medicine. Medidata’s unified eClinical platform includes the Rave Data Capture and Management family of products, which seamlessly captures and integrates the abundance of data streams and biomarker measurements that targeted therapies demand, from clinics and labs to sensors, apps, images, genomics and RWE (Real World Evidence). On the same platform, the Edge Trial Planning and Management family enable the research team with historical benchmarks and automation capabilities to optimize patient burden, site selection, grants, and payments. All Medidata product families are powered by the Medidata Enterprise Data Store (MEDS) - the most modern, scalable data backbone available in research, which allows sponsors and CROs to collaborate, powering cross-sponsor, cross-study analytics.


About Medidata

Medidata's unified platform, pioneering analytics, and unrivaled expertise power the development of new therapies for over 1,000 pharmaceutical companies, biotech, medical device firms, academic medical centers and contract research organizations around the world. The Medidata Clinical Cloud® connects patients, physicians and life sciences professionals. Companies on the Medidata platform are individually and collaboratively reinventing the way research is done to create smarter, more precise treatments. For more information: www.mdsol.com

1 Clinical Development Success Rates 2006-2015, BIO, Biomedtracker, Amplion

Back to HCB News

Health IT Homepage